SCHEMBL13665241

SCHEMBL13665241

Nc1c(C(=O)Nc2ccc(Cl)cn2)oc2cc(C(=O)O)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 8/20 0.53
▸ RAB9A P51151 11/20 0.49
▸ NPC1 O15118 9/20 0.49
▸ NFKB1 P19838 3/20 0.49
▸ NFKB2 Q00653 3/20 0.49
▸ RELA Q04206 3/20 0.49
▸ TP53 P04637 3/20 0.49
▸ TSHR P16473 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ SORT1 Q99523 1/20 0.47
▸ KMT2A Q03164 5/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2941972 0.91 SMN1; SMN2 (0.55) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2947441 0.89 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13665243 0.88 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13665212 0.86 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13665211 0.86 SORT1 (0.57) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13515797 0.86 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13291233 0.85 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13665204 0.83 RAB9A (0.55) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13515796 0.83 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2945692 0.83 SMN1; SMN2 (0.74) SMN1; SMN2RAB9ANPC1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885RAB9A 4600/4885NPC1 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback